Page 1 | Search Results | Blood | American Society of Hematology

1-15 of 15

Sort by

Sort Order Select

Journal Articles

The Role of Alpha 2 Macroglobulin in Chronic Activation of the Complement System in Patients with Chronic Lymphocytic Leukemia

Naseba Naseraldeen, M.A., Regina Michelis, D.Sc, Masad Barhoum, MD, Judith Chezar, PhD, Tamar Tadmor, MD, Ariel Aviv, MD, Lev Shvidel, MD, Adi Litmanovich, Mona Yuklea, MD, Mona Shehadeh, PhD, Ety Shaoul, PhD, Andrei Braester, MD

Blood (2020) 136 (Supplement 1): 17.

https://doi.org/10.1182/blood-2020-141198

Published: 2020

Journal Articles

Decreased Iron Overload and Oxidative Stress in Transfusion Dependent Patients with Myelodysplastic Syndromes (MDS) with the Oral Iron Chelator Deferiprone

Drorit Merkel, MD, Shelly Soffer, Kalman Filanovsky, MD, Andrei Braester, MD, Eitan Fibach, PhD, Mutaz Mohammad Dana, Yishay Ofran, MD, Uri Greenbaum, MD, Arnon Nagler, MD, Moshe Mittelman, MD

Blood (2018) 132 (Supplement 1): 4381.

https://doi.org/10.1182/blood-2018-99-115157

Published: 2018

Journal Articles

A Novel Risk-Model to Predict Time to First Treatment (TTT) in Chronic Lymphocytic Leukemia Based on Heavy+Light Chain Immunoparesis and Serum Free Light Chain Analysis: Results from the Israeli CLL Study Group

Tamar Tadmor, MD, Andrei Braester, MD, Najib Dally, MD, Ariel Aviv, Yair Herishanu, MD, Mona Yuklea, MD, Lev Shvidel, MD, Naomi Rahimi-Levene, MD, Rosa Ruchlemer, MD, Ariela Arad, MD, Claudia Fogl, MD, Aaron Polliack, MD, Lee Magal, PhD, Kelly Townsend, PhD

Blood (2018) 132 (Supplement 1): 1849.

https://doi.org/10.1182/blood-2018-99-113771

Published: 2018

Journal Articles

Tissue Molecular Genotyping Improves Patient Blood Management in Syrian Injured Patients Treated in Israel

Luiza Akria, MD, Masad Barhoum, Simona Zisman-Rozen, Celia Suriu, Andrei Braester, MD, Ety Shaoul

Blood (2018) 132 (Supplement 1): 5076.

https://doi.org/10.1182/blood-2018-99-114061

Published: 2018

Journal Articles

Results of a Phase II of Low-Dose Fludarabine and Cyclophosphamide Combined with Standard Dose Rituximab (FCR-LITE) in Elderly, Untreated Patients with Chronic Lymphocytic Leukemia (CLL): The Israeli CLL Study Group Experience

Tamar Tadmor, MD, Yair Herishanu, MD, Andrei Braester, MD, Osnat Bairey, MD, Ariel Aviv, Naomi Rahimi-Levene, MD, Riva Fineman, MD, Itai Levi, MD, Mona Yuklea, MD, Rosa Ruchlemer, MD, Lev Shvidel, MD, Aaron Polliack, MD

Blood (2018) 132 (Supplement 1): 5566.

https://doi.org/10.1182/blood-2018-99-111681

Published: 2018

Journal Articles

Clinical Benefit and Improvement of Mitochondrial Function in Low Risk Myelodysplastic Syndrome Treated By Combination Ultra Coenzyme Q10 and L-Carnitine

Kalman Filanovsky, Michal Haran, MD, Vita Mirkin, PhD, Andrei Braester, MD, Olga Shvetz, MD, Anfisa Stanevsky, MD, Erica Sigler, MD, Ekaterina Votinov, MD, Yehudit Zaltsman-Amir, PhD, Atan Gross, PhD, Lev Shvidel, MD

Blood (2017) 130 (Supplement 1): 1704.

https://doi.org/10.1182/blood.V130.Suppl_1.1704.1704

Published: 2017

Journal Articles

High Peripheral Blood Circulating BDNF Levels Are Associated with Good Prognosis in CLL Patients; A CXCR-4 Dependent Effect?

David Azoulay, PhD, Yair Herishanu, MD, Mika Shapiro, PhD, Yarden Brenshaft, Celia Suriu, MD, Luiza Akria, MD, Andrei Braester, MD

Blood (2016) 128 (22): 5562.

https://doi.org/10.1182/blood.V128.22.5562.5562

Published: 2016

Journal Articles

Efficacy and Safety of Frontline Therapy with "FCR" Regimen for Chronic Lymphocytic Leukemia Outside Clinical Trials: Israeli CLL Study Group Experience

Yair Herishanu, MD, Neta Goldschmidt, MD, Osnat Bairey, MD, Rosa Ruchlemer, MD, Riva Fineman, MD, Naomi Rahimi-Levene, Lev Shvidel, MD, Tamar Tadmor, MD, Ariel Aviv, MD, Andrei Braester, MD, Erel Joffe, MDMSc, Aaron Polliack, MD

Blood (2014) 124 (21): 5659.

https://doi.org/10.1182/blood.V124.21.5659.5659

Published: 2014

Journal Articles

Ruxolitinib Treatment for Myelofibrosis: Efficacy and Tolerability in a Real-World Setting

Martin H. Ellis, MD, Noa Lavi, MD, Elena Mishchenko, MD, Najib Dally, MD, David Lavie, MD, Anna Courevitch, MD, Odit Gutwein, MD, Shlomo Bulvik, MD, Andrei Braester, MD, Evgeni Chubar, MD, Sigal Tavor, MD, Adrian Duek, MD, Ilya Kirgner, MD, Maya Koren-Michowitz, MD

Blood (2014) 124 (21): 1830.

https://doi.org/10.1182/blood.V124.21.1830.1830

Published: 2014

Journal Articles

Alterations in Platelet Levels of Brain-Derived Neurotrophic Factor Are Associated with Clinical Response to Bortezomib in Patients with Multiple Myeloma

David Azoulay, PhD, Celia Suriu, MD, Luiza Akria, MD, Netanel A Horowitz, MD, Andrei Braester, MD

Blood (2014) 124 (21): 2252.

https://doi.org/10.1182/blood.V124.21.2252.2252

Published: 2014

Journal Articles

Azacitidine and Lenalidomide Combination In Higher-Risk Myelodysplastic Syndromes-Preliminary Results Of The Vilen-01 Protocol

Moshe Mittelman, MD, Kalman Filanovsky, MD, Hanna Rosenbaum, MD, Pia Raanani, MD, Andrei Braester, MD, Neta Goldschmidt, MD, Ilana Hellman, PhD, Ilya Kirgner, MD, Chava Perri, Howard S Oster, MD, PhD

Blood (2013) 122 (21): 1576.

https://doi.org/10.1182/blood.V122.21.1576.1576

Published: 2013

Journal Articles

Bortezomib Induced Peripheral Neuropathy Is Related to Altered Level of Brain Derived Neurotrophic Factor in the Circulating Blood.

David Azoulay, David Lavie, MD, Moshe E. Gatt, MD, Celia Surio, Luiza Akaria, Riki Perlman, Andrei Braester, MD, Dina Ben Yehuda, M.D.

Blood (2012) 120 (21): 2819.

https://doi.org/10.1182/blood.V120.21.2819.2819

Published: 2012

Journal Articles

Predictive Parameters for Infections During Azacitidine Therapy in High Risk MDS Patients,

Drorit Merkel, MD, Kalman Filanovsky, MD, Ariel Aviv, MD, Moshe E. Gatt, MD, Yair Herishanu, MD, Ariela Arad, MD, Tamar Tadmor, MD, Najib Dally, MD, Aharon Ronson, MD, Luiza Akria, MD, Andrei Braester, MD, Arnon Nagler, MD, Ronit Leiba, MSc., Yishai Ofran, MD

Blood (2011) 118 (21): 3811.

https://doi.org/10.1182/blood.V118.21.3811.3811

Published: 2011

Journal Articles

Presenting Features and Outcome of Elderly Chronic Lymphocytic Leukemia Patients Diagnosed at the Age of 80 Years or Above. An ICLLSG Study.

Osnat Bairey, Rosa Ruchlemer, MD, Naomi Rahimi-Levene, Yair Herishanu, MD, Andrei Braester, MD, Abraham Klepfish, MD, Lev Shvidel

Blood (2010) 116 (21): 4620.

https://doi.org/10.1182/blood.V116.21.4620.4620

Published: 2010

Journal Articles

Massive Transfusion in Wartime: Experience from Northern Israel, Summer 2006.

Eldad J. Dann, MD, Najib Dally, MD, Judith Chezar, PhD, Moshe Michaelson, MD, Mirit Barzelay, Andrei Braester, MD, Ron Hoffman, MD, Lilach Bonstein, PhD

Blood (2007) 110 (11): 4017.

https://doi.org/10.1182/blood.V110.11.4017.4017

Published: 2007

NARROW

The Role of Alpha 2 Macroglobulin in Chronic Activation of the Complement System in Patients with Chronic Lymphocytic Leukemia

Decreased Iron Overload and Oxidative Stress in Transfusion Dependent Patients with Myelodysplastic Syndromes (MDS) with the Oral Iron Chelator Deferiprone

A Novel Risk-Model to Predict Time to First Treatment (TTT) in Chronic Lymphocytic Leukemia Based on Heavy+Light Chain Immunoparesis and Serum Free Light Chain Analysis: Results from the Israeli CLL Study Group

Tissue Molecular Genotyping Improves Patient Blood Management in Syrian Injured Patients Treated in Israel

Results of a Phase II of Low-Dose Fludarabine and Cyclophosphamide Combined with Standard Dose Rituximab (FCR-LITE) in Elderly, Untreated Patients with Chronic Lymphocytic Leukemia (CLL): The Israeli CLL Study Group Experience

Clinical Benefit and Improvement of Mitochondrial Function in Low Risk Myelodysplastic Syndrome Treated By Combination Ultra Coenzyme Q10 and L-Carnitine

High Peripheral Blood Circulating BDNF Levels Are Associated with Good Prognosis in CLL Patients; A CXCR-4 Dependent Effect?

Efficacy and Safety of Frontline Therapy with "FCR" Regimen for Chronic Lymphocytic Leukemia Outside Clinical Trials: Israeli CLL Study Group Experience

Ruxolitinib Treatment for Myelofibrosis: Efficacy and Tolerability in a Real-World Setting

Alterations in Platelet Levels of Brain-Derived Neurotrophic Factor Are Associated with Clinical Response to Bortezomib in Patients with Multiple Myeloma

Azacitidine and Lenalidomide Combination In Higher-Risk Myelodysplastic Syndromes-Preliminary Results Of The Vilen-01 Protocol

Bortezomib Induced Peripheral Neuropathy Is Related to Altered Level of Brain Derived Neurotrophic Factor in the Circulating Blood.

Predictive Parameters for Infections During Azacitidine Therapy in High Risk MDS Patients,

Presenting Features and Outcome of Elderly Chronic Lymphocytic Leukemia Patients Diagnosed at the Age of 80 Years or Above. An ICLLSG Study.

Massive Transfusion in Wartime: Experience from Northern Israel, Summer 2006.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only